T. Rowe Price Associates
TCRX icon

T. Rowe Price Associates’s TScan Therapeutics TCRX Stock Holding History

T. Rowe Price Associates’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,479
Closed -$22K – 3147
2025
Q1 		$22K Hold
15,479
– – ﹤0.01% 3002
2024
Q4 		$48K Buy
15,479
+3,178
+26% +$14.4K ﹤0.01% 2949
2024
Q3 		$62K Hold
12,301
– – ﹤0.01% 2904
2024
Q2 		$0 Buy
+12,301
New +$96.9K ﹤0.01% 3028

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

T. Rowe Price Associates's TCRX Position: Q2 2025 in Review

T. Rowe Price Associates sold out of TScan Therapeutics (TCRX) in Q2 2025, closing a stake of 15,479 shares — an estimated $22K sold.

T. Rowe Price Associates first reported a position in TCRX in Q2 2024 and held it in 4 quarters. The position peaked at $62K in Q3 2024. 81 funds tracked by Wall St. Rank hold TCRX as of Q2 2025.

  • T. Rowe Price Associates reported no remaining TScan Therapeutics position as of Q2 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 15,479 TScan Therapeutics shares in Q2 2025, an estimated $22K.
  • T. Rowe Price Associates first reported a position in TScan Therapeutics in Q2 2024 and held it in 4 quarters.
  • T. Rowe Price Associates's TScan Therapeutics position peaked at $62K in Q3 2024.
  • 81 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.